Alzheimer's Disease

This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer's And Parkinson's Diseases
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
EXCLUSIVE: New Alzheimer's Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
EXCLUSIVE: New Alzheimer's Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Could CBD Revolutionize Alzheimer's Treatment? New Study Explores Its Neuroprotective Properties

Alzheimer's Disease Recent News

THC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic Communities
IGC Pharma, Inc.
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Exclusive: FloraWorks Completes $2.25M Series-A Financing For Cannabinoid Research
FloraWorks, a cannabinoid therapeutics company specializing in rare and novel cannabinoids, has successfully completed a $2.25 million Series-A financing round. Leading this significant investment was life sciences venture capital firm, Bonaventure Equity LLC.
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
Study Shows Positive Results In Patients With Alzheimer's Disease And Agitation
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.
EXCLUSIVE: Cognition Therapeutics Shares Biomarker Data From Alzheimer's Candidate
Cognition Therapeutics Inc (NASDAQ: CGTX) presented a proteomic analysis of clinical biomarker data from the SPARC study of CT1812 in mild-to-moderate Alzheimer's disease at the Alzheimer's Association International Conference. 
AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease.
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall
Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after 
EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial
Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial. 
Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes
Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&
EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal
Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal.
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have 
Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks
Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs
Prothena Corporation plc (NASDAQ: PRTA) 
Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial
AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a
Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report
Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a 
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
The